Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Reasons for optimism in the therapy of acute leukemia.

Best practice & research. Clinical haematology - 1 Jan 2000

Rowe Jacob M

Abstract excerpt

Distinct progress has been made in recent years in the therapy of acute leukemia. For acute myeloid leukemia (AML), this progress has been anchored in the increased understanding of genomic complexity. Multiple targets and the relationships among them pose new challenges along with new possibilities for the development of targeted therapies. A number of new drugs are in early clinical development for AML, one of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Survival Analysis
Share to T-Lymphocytes
Share to Antibodies, Bispecific

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Epigenesis, Genetic

Share to Isocitrate Dehydrogenase

Share to Leukemia, Myeloid, Acute

Share to Molecular Targeted Therapy

Share to Precursor Cell Lymphoblastic Leukemia-Lymphoma

Source

Identifiers

PMID: 26590761
DOI: 10.1016/j.beha.2015.10.002

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Reasons for optimism in the therapy of acute leukemia.PMID 26590761Read ↗

How I treat acute myeloid leukemia in the era of new drugs.Semantic proximity Read ↗

Update on current treatments for adult acute myeloid leukemia: to treat acute myeloid leukemia intensively or non-intensively? That is the question.Semantic proximity Read ↗

Efficacy and tolerability of isocitrate dehydrogenase inhibitors in patients with acute myeloid leukemia: A systematic review of clinical trials.Semantic proximity Read ↗

Clinical Implications of Isocitrate Dehydrogenase Mutations and Targeted Treatment of Acute Myeloid Leukemia with Mutant Isocitrate Dehydrogenase Inhibitors-Recent Advances, Challenges and Future Prospects.Semantic proximity Read ↗

The most novel of the novel agents for acute myeloid leukemia.Semantic proximity Read ↗

Novel therapies in AML: reason for hope or just hype?Semantic proximity Read ↗

Histone deacetylase inhibitors: targeting epigenetic regulation in the treatment of acute leukemiaSemantic proximity Read ↗

Towards precision medicine for AML.Semantic proximity Read ↗

Epigenetic Therapy in Acute Myeloid Leukemia: Current and Future Directions.Semantic proximity Read ↗

Practical considerations in clinical application of WHO 5th and ICC classification schemes for acute myeloid leukemia.Semantic proximity Read ↗

Aldehyde dehydrogenases in acute myeloid leukemiaSemantic proximity Read ↗

Four Decades of Molecular Innovation in Chronic Myeloid Leukemia: From Antisense Targeting to Treatment-Free RemissionSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.